Invasive Aspergillosis (IA) is a dreaded infectious complication among immunocompromised patients, including those receiving treatment for hematologic malignancies. Preemptive diagnosis of IA, using serum markers alone or in combination with computed tomography (CT), has received significant attention over the last decade but remains controversial. [1] [2] [3] In 2003, an ELISA to detect serum galactomannan (GM) was approved by the US Food and Drug Administration. 4 In a meta-analysis of 27 studies using the GM assay for surveillance, the sensitivity and specificity were 71 and 80%, respectively, for cases of definite IA. However, there was significant heterogeneity among studies. Also, most studies of serum GM have included patients with acute leukemia or allogeneic hematopoietic SCT recipients. In these populations, the risk for IA varies between 5 and 15%. [5] [6] [7] [8] [9] In contrast, IA among autoSCT recipients is significantly less common, ranging between 0 and 8%. 5, [7] [8] [9] This lower risk raises the question whether the GM assay has utility among auto-SCT recipients.
Memorial Sloan-Kettering Cancer Center (MSKCC) is a tertiary care cancer center in New York City. Medical and laboratory records were reviewed for all patients who underwent auto-SCT at MSKCC between September 2003 and June 2007. The study was approved by the MSKCC Institutional Review Board. NIAID/MSG criteria 10 were used to categorize definite, probable or possible IA. Moldactive prophylaxis was not routinely given to patients undergoing auto-SCT, but was administered to a limited number of patients at the treating physician's discretion.
Galactomannan assays were performed only at the treating physician's discretion, generally in response to persistent fever and neutropenia or the development of pulmonary lesions identified by CT. A positive serum GM was defined as X0.500. The Student's t-test was used to compare continuous variables. STATA software (version 7) was used to calculate the area under the receiver operating characteristic (ROC) curve.
During the study period, 583 patients received 698 autoSCTs (Table 1) . Of the 583 patients, 43 (7.4%) underwent 91 GM assays (Table 1) . Ten (23.3%) of the 43 patients received peri-transplant prophylaxis with a mold-active antifungal, 29 (67.4%) received fluconazole and 4 (9.3%) received no antifungal prophylaxis. Twenty-three (53.5%) patients received mold-active antifungal therapy within 72 h before their first serum GM.
The patients who underwent GM testing tended to be younger and more frequently male than the remaining population ( Table 1 ). The spectrum of malignancies also differed between the groups, with a greater proportion of patients who underwent GM testing having Hodgkin's lymphoma (32.6 vs 12.6%) ( Table 1) .
Only 2 (2.2%) of 91 GM assays were positive, both from the same patient who received a second auto-SCT for multiple myeloma. He also grew Aspergillus fumigatus from sputum specimens. He died despite a 36-day course of combination therapy with voriconazole and micafungin. An autopsy confirmed the presence of pulmonary mold infection. No other patients had positive GM assays. None of the other 582 patients who underwent auto-SCT had a positive culture for mold by day þ 100 after transplant.
Beside the one patient with definite IA, none had probable IA, 14 had possible IA based on CT of the chest, and 28 were found to have no evidence of IA. Assuming that all patients with definite, probable or possible IA had IA infection, the sensitivity of the GM assay was 6.7%. The mean (0.117 vs 0.106; P ¼ 0.37) and range of GM values for patients with possible IA mirrored the range among patients with no evidence of IA (Figure 1) . ROC analysis illustrated a minimal improvement of the GM assay over chance, with an area under the ROC curve ¼ 0.5857.
Differences in treatment appeared to depend on clinical factors rather than GM assay values. The 14 patients who were found to have possible or definite IA received prolonged courses (mean, 52 days; median, 25 days) of mold-active therapy. In contrast, patients who underwent GM testing but had no evidence of IA received shorter courses (mean, 17 days; median, 7 days).
Five additional patients were believed to have fungal infection based on ICD-9 coding, but they did not undergo GM testing. All had possible IA, and two were diagnosed with possible IA before auto-SCT and continued on voriconazole through the transplant period.
The serum GM assay has been used both as a preemptive screen, typically on a weekly or twice-weekly basis, and as a diagnostic test in the setting of clinical signs or symptoms, in patients at high-risk for IA. The risk of IA among patients receiving auto-SCT is significantly lower than that among high-risk groups such as allo-SCT recipients. In our series, only 19 (3.3%) of 583 auto-SCT recipients developed possible, probable or definite IA, and only one of these had a positive culture for Aspergillus, a positive GM assay or consistent pathologic findings, raising the likelihood that the true frequency of IA was much lower. It is noted that none of the patients with possible IA had GM values 40.2 and that the spectrum of values in these patients did not differ from those with no evidence of IA (Figure 1) . Thus, the lower risk of IA among auto-SCT recipients makes the cost and effort of a preemptive approach difficult to justify. Instead, we use the GM assay solely in the setting of clinical suspicion for IA, either because of pulmonary symptoms, findings on CT imaging or persistent fever.
Empiric mold-directed therapy was common in our population and may have contributed to the low rate of positive GM assays. Patients with possible IA received a median of 25 days of anti-mold therapy, despite having one or more negative GM assays. Thus, treating physicians generally did not value the assay as a negative predictor of IA.
We used the GM assay as a diagnostic test for IA within the first 100 days after auto-SCT. In our experience, this approach was not helpful for confirming or excluding the diagnosis of IA and did not appreciably influence management decisions regardless of test results.
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